A Mathematical Model of Immune-System-Melanoma Competition
暂无分享,去创建一个
[1] Lieping Chen,et al. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. , 2002, Cancer research.
[2] Lieping Chen,et al. Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.
[3] G. Zhu,et al. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. , 2010, Blood.
[4] M. Colombo,et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. , 2006, Cancer research.
[5] Francesco Pappalardo,et al. SimB16: Modeling Induced Immune System Response against B16-Melanoma , 2011, PloS one.
[6] J. Peppard,et al. The biological half-lives of four rat immunoglobulin isotypes. , 1980, Immunology.
[7] I. Melero,et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. , 2011, Cancer research.
[8] B. Sangro,et al. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? , 2009, Immunotherapy.
[9] Fumito Ito,et al. Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.
[10] Y. Lotan,et al. Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians , 2002, Prostate Cancer and Prostatic Diseases.
[11] Laird Ak. DYNAMICS OF TUMOR GROWTH. , 1964 .
[12] Francesco Pappalardo,et al. Agent Based Modeling of Lung Metastasis-Immune System Competition , 2009, ICARIS.
[13] W. Clark,et al. The developmental biology of primary human malignant melanomas. , 1975, Seminars in oncology.
[14] Drew M. Pardoll,et al. Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.
[15] I. Melero,et al. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. , 2008, Trends in pharmacological sciences.
[16] Lieping Chen,et al. Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination , 2009, Clinical Cancer Research.
[17] Francesco Pappalardo,et al. Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.
[18] D. Kirschner,et al. A methodology for performing global uncertainty and sensitivity analysis in systems biology. , 2008, Journal of theoretical biology.
[19] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[20] J. Heath. Biology of the Cell Cycle , 2008 .
[21] Lieping Chen,et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ , 2010, Cancer Immunology, Immunotherapy.
[22] D. Pardoll. T cells take aim at cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.